FDA Grants Rare Pediatric Disease Designation to Omeros’ Masp-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy
FDA授予奧麥羅製藥的Masp-3抑制劑Zaltenibart罕見兒童疾病認定,用於治療C3腎小球病
FDA Grants Rare Pediatric Disease Designation to Omeros’ Masp-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy
FDA授予奧麥羅製藥的Masp-3抑制劑Zaltenibart罕見兒童疾病認定,用於治療C3腎小球病
譯文內容由第三人軟體翻譯。